Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T.
Shiqi L, Jiasi Z, Lvzhe C, Huailong X, Liping H, Lin L, Qianzhen Z, Zhongtao Y, Junjie S, Zucong C, Yingzi Z, Meiling W, Yunyan L, Linling W, Lihua F, Yingnian C, Wei Z, Yu L, Le L, Youcheng W, Dingsong Z, Yancheng D, Ping Y, Lihua Z, Xiaoping L, Xiaozhuang H, Zhongzheng Z, Zhi Y, Cheng Q, Sanbin W.
Shiqi L, et al.
Mol Ther Oncolytics. 2023 Apr 20;29:107-117. doi: 10.1016/j.omto.2023.04.003. eCollection 2023 Jun 15.
Mol Ther Oncolytics. 2023.
PMID: 37215385
Free PMC article.
It is of great clinical significance to explore which factors will impact long-term disease-free survival of patients with r/r B-ALL after CAR-T therapy without bridging bone marrow transplantation. Our study found that, in patients with r/r B-ALL without bridging transpla …
It is of great clinical significance to explore which factors will impact long-term disease-free survival of patients with r/r B-ALL …